SLS

SELLAS Life Sciences Group Inc.

Price

$11.74

return (12m)

527.81%

p/e

-69.08

p/bv

16.29

DIVIDEND YIELD

0.00%

SLS price

SELLAS Life Sciences Group

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment SLS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-15.30%

3 months

-12.22%

1 year

527.81%

2 years

831.75%

5 years

39.10%

10 years

-99.87%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals SLS

Valuation

P/E

-69.08

Sector -3.34

Industry -3.34

P/BV

16.29

Sector 1.90

Industry 1.90

P/Revenue (PSR)

Sector 2.02

Industry 2.02

EV/EBITDA

-197.97

Sector -218.52

Industry -218.52

EV/EBIT

-197.97

Sector -48.04

Industry -48.04

P/EBITDA

-63.67

Sector -22.59

Industry -22.59

P/EBIT

-63.67

Sector -30.09

Industry -30.09

P/Total Assets

15.43

Sector 1.12

Industry 1.12

P/Net Current Assets

16.64

Sector -9.63

Industry -9.63

P/Working Capital

16.62

Sector -160.04

Industry -160.04

EPS

-0.17

Sector -1.78

Industry -1.78

BVPS

0.73

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

0.00%

Sector 41.35%

Industry 41.35%

EBITDA Margin

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

0.00%

Sector -35.47%

Industry -35.47%

Net Profit Margins

0.00%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-23.58%

Sector -57.36%

Industry -57.36%

ROA

-22.33%

Sector -59.44%

Industry -59.44%

ROIC

-955.95%

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

18.83

Sector 2.91

Industry 2.91

Net Debt / EBITDA

13.02

Sector -21.98

Industry -21.98

Net Debt / EBIT

13.02

Sector -8.44

Industry -8.44

Net Debt / Equity

-1.00

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.95

Sector 0.46

Industry 0.46

Liabilities/Assets

0.05

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

9.42%

Sector -

Industry -

Fundamentals SLS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
SLS SELLAS Life Sciences Group Inc.	$11.74	527.81%	0.00%	-69.08	16.29	-23.58%	0.00%
PFE Pfizer Inc.	$27.80	8.72%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$262.82	15.95%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.32	-34.29%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$144.30	68.14%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$156.90	-6.45%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$61.15	42.37%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$69.69	-51.49%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$403.04	39.03%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$735.20	23.02%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$109.86	59.26%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$902.28	22.73%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$504.73	25.15%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$228.30	49.71%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$919.21	14.90%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.64	45.31%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$219.88	37.53%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

SLS - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT SELLAS Life Sciences Group

SELLAS Life Sciences Group Inc.

Average Investor10 user rating

4.0 (3 people)

United States

20 years

Founded: 2006

2008

Time since IPO - 18 years

7

Employees

SELLAS Life Sciences Group Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.24 billion, with shareholders equity totaling $137.66 million.

The company employs approximately 7 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, SELLAS Life Sciences Group Inc. reported $- in revenue, generating net income of $-32.46 million.

Key financial metrics include a P/E ratio of -69.08, a price-to-book (P/B) ratio of 16.29, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker SLS.

Market cap

$2.24 billion

Net worth

$137.66 million

$137,656,000.00

Assets

$145.38 million

$145,382,000.00

Total Shares Outstanding

189.18 million

189,183,000

Average Daily Trading Volume

$6.66 million

$6,664,876.00

Sector

Health Care

Industry

Biotechnology

SLS

SLS revenue and profits

Financial Results SLS

DRAG THE FRAME TO SEE MORE DATA

SLS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$902.28 22,73% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$228.30 49,71% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$262.82 15,95% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$144.30 68,14% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$156.90 --6,65% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$27.80 8,72% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$61.15 42,37% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$902.28 22,73% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$228.30 49,71% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$262.82 15,95% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$144.30 68,14% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$156.90 --6,65% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$27.80 8,72% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$61.15 42,37% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of SELLAS Life Sciences Group (SLS) today?

The current price of SELLAS Life Sciences Group (SLS) is $11.74. The stock began the year trading around $3.77 and is currently priced at $11.74. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does SELLAS Life Sciences Group (SLS) pay dividends?

SELLAS Life Sciences Group (SLS) did not pay dividends over the past year.

Is SELLAS Life Sciences Group (SLS) a good investment?

SELLAS Life Sciences Group (SLS) is currently trading at $11.74 with a P/E ratio of -69.08. This represents a -1,816% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 527.81%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy SELLAS Life Sciences Group (SLS) stock?

You can buy SELLAS Life Sciences Group (SLS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol SLS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of SELLAS Life Sciences Group (SLS) yield today?

Over the past month, SELLAS Life Sciences Group (SLS) has returned -15.30% — 527.81% over the past year, and 39.10% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of SELLAS Life Sciences Group (SLS) today at the current price of $11.74 your total investment would be $1,174.00.

Based on historical performance, the investment would have grown to approximately:

$7,370.49 after 1 year
$1,633.03 after 5 years
$1.53 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

SLS

SELLAS Life Sciences Group Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment SLS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING SLS WITH OTHER STOCK

ABOUT SELLAS Life Sciences Group

SELLAS Life Sciences Group Inc.

United States

20 years

2008

7

PROFIT X PRICE SLS

Financial Results SLS

SLS cash flow

Asset, Revenue and Profit Growth - SLS

SLS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions